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A B S T R A C T   
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 
set in the recently approved global strategy for cervical cancer elimination as a public health problem. 
As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most 
introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- 
and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for 
the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 
(6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose 
coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated 
at 15%. 
There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, 
specially ensuring the most populous countries introduce, and further improving program performance globally.   
1. Introduction 
Cervical cancer, caused by infections from the human papillomavirus 
(HPV), is a major public health problem, especially in low- and middle- 
income countries (LMIC). Vaccines against HPV have been available 
since 2006 and recommended by World Health Organization (WHO) 
since 2009 (World Health Organization, 2009; World Health Organiza-
tion, 2014; World Health Organization, 2017; World Health 
Organization, 2019a). They have been progressively introduced in many 
national immunization schedules, but several studies and international 
agencies have reported that both vaccine introduction and coverages 
achieved are still sub-optimal (Drolet et al., 2019; Gallagher et al., 2018; 
LaMontagne et al., 2017; World Health Organization, 2018a). In 2016, it 
was estimated that HPV immunization programs targeted only 12% of 
young adolescent females worldwide, and only 6% of girls aged 10–20 
had been vaccinated by end 2014 (Bruni et al., 2016). 
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Given the highly effective and cost-effective prevention strategies 
available and the growing inequalities worldwide, in May 2018 the 
WHO Director-General made a global call for action towards the elimi-
nation of cervical cancer as a public health problem (hereafter referred 
to as elimination), aiming to reduce the annual incidence below 4 cases 
per 100,000 globally (World Health Organization, 2018b; World Health 
Organization, 2018c). The WHO Cervical Cancer Elimination strategy 
includes coverage targets for scale-up by 2030 of HPV vaccination to 
90% of all adolescent girls, twice-lifetime cervical screening to 70%, and 
treatment of pre-invasive lesions and invasive cancer to 90% (World 
Health Organization, 2019b). This target is aligned with the Immuni-
zation Agenda 2030 and the Sustainable Development Goals (SDGs) 
agenda (SDGs 3.4 and 3.b.1) (World Health Organization, 2020a; United 
Nations, 2015). The global strategy may be the accelerator needed to 
complete the introduction worldwide and improve HPV vaccine 
coverage globally. 
This paper aims to describe the current status (by mid 2020) of HPV 
vaccine introduction and main characteristics of vaccination programs, 
alongside the results from the second edition of historical series of 
WHO/UNICEF coverage estimates for HPV vaccination released in July 
2020 with 2010 to 2019 data (World Health Organization, 2020b). This 
work intends to provide more insight on where we stand on the path 
towards elimination. HPV vaccination coverage is one of the key in-
dicators of the Cervical Cancer elimination strategy, as it tracks the 
performance of vaccination programs and proxies the potential impact 
on future HPV-related disease burden (Dillner et al., 2010). The long- 
term impact of the elimination campaign will depend primarily on the 
extension and success of the HPV vaccination programs (Brisson et al., 
2020). 
2. Methods 
2.1. Data sources 
This work presents the WHO/UNICEF Estimates of National HPV 
Immunization Coverage from 2010 to 2019 (World Health Organization, 
2020b). These estimates are derived from the administrative and survey 
data reported annually to WHO through the WHO/UNICEF Joint 
Reporting Form (JRF) (World Health Organization, 2020c). WHO/ 
UNICEF estimation methods of HPV vaccine coverage are explained in 
more detail in Supplementary material - section 1 and Supplementary 
Figs. 1–4. This methodology differs from that used for other vaccines and 
was reviewed and approved by the Immunization and Vaccine related 
Implementation Research Advisory Committee (IVIR-AC) in March 2019 
(World Health Organization, 2019c). 
WHO/UNICEF produce two main coverage indicators for HPV 
vaccination: the HPV vaccination Program performance coverage which 
describes the vaccination coverage according to the national schedule 
and the program’s eligibility criteria for each calendar year (program’s 
target population up to 14 years of age), and the HPV vaccination 
coverage by age 15 that represents the proportion of population turning 
15 in the reporting year that have been vaccinated against HPV at any 
time between ages 9 to 14, at any time up to the calendar year in 
question. See Supplementary material - section 1 for more information 
on their use and limitations. Data are always reported at the national 
level and may not necessarily show differences at the sub-national level. 
Both indicators are calculated for the first dose (HPV1) and the full 
recommended schedule (HPVc) and by sex. For the vaccines currently on 
the market, the vaccination schedule depends on the age. The general 
recommendation is a 2-dose schedule minimum 6 months apart for in-
dividuals under 15 years of age at the time of the first dose, and a 3-dose 
schedule (0, 1–2, 6 months) for individuals 15 years of age or older, 
immunocompromised or with HIV infection (World Health Organiza-
tion, 2017; World Health Organization, 2019a). In some countries, 
alternative schedules with extended time intervals between doses are 
also applied (World Health Organization, 2019a). 
2.2. Statistical analyses 
Global and regional coverages for each calendar year were calculated 
as the population weighted average of country-specific estimates using 
the HPV vaccine program performance coverage indicator (see Supple-
mentary material - section 1) and official United Nations (UN) popula-
tion estimates and projections that are prepared by the Population 
Division of the Department of Economic and Social Affairs of the UN 
Secretariat (United Nations, Department of Economic and Social Affairs, 
Population Division, 2019). Weighted average coverage estimates 
include all 194 WHO Member States. A WHO Member State is consid-
ered to have an HPV vaccination program as per the WHO definition of 
introduced, when the country reports in the JRF to have officially 
included HPV vaccination in their national immunization schedule 
either at national or subnational level. Members states considered not 
have introduced or without coverage data had a 0% coverage assigned. 
95% bootstrap confidence intervals were estimated using the percentile 
method (3000 replications). A sensitivity analysis was conducted to 
assess the impact of these 0% coverage values, imputing alternative 
values of 50% and extreme 100% for countries with a program and no 
coverage data. No significant impact was observed on global coverage. 
(Supplementary Fig. 5). In addition, we calculated an unweighted 
average coverage among countries with valid performance coverage 
estimates. 
Estimates are presented under different regional groupings: by in-
come level using the 2019 World Bank’s classification (World Bank, 
2019), the UN Sustainable Development Goals (SDGs) geographical re-
gions (United Nations, Department of Economic and Social Affairs, 
Statistics Division, 2016), the six WHO regions, with a regional office 
each (World Health Organization, 2020d), and by Gavi-eligibility (Gavi, 
the Vaccine Alliance, 2018). Throughout this article, we used the 
following acronyms for country income level groupings: High Income 
Countries (HIC), Low- and Middle-Income Countries (LMIC). 
To assess if there were differences on the performance between the 
first years of the program and the following years, box-plot graphs were 
created and tested with the Wilcoxon signed-rank test for paired data for 
means and Imam test of scale for paired samples for the homogeneity of 
variance. Only 53 programs introduced before 2018 and with data for at 
least the first two years and subsequent years were included. Coverage 
datapoints estimated by extrapolation or interpolation, subnational es-
timates or 99% truncated estimates were excluded. For the first-two- 
years period, if estimates were available for both years, the second 
year was prioritized. For countries that introduced before 2010, as WHO 
does not produce earlier estimates, the first-year estimate was consid-
ered that of 2010. As the coverage for the following years, the mean of 
all available coverages from the third year onwards was used. The re-
sults were stratified by income level and a 50% threshold of the first- 
two-years coverage. A sensitivity analysis was performed excluding 
small countries (N=19), but no differences were found. 
3. Results 
As of June 2020, 107 (55%) of the 194 WHO Member States are 
considered to have introduced HPV vaccination nationwide or partially 
as per WHO definition. As shown in Fig. 1, the extent of the introduction 
is not equally distributed geographically. The Americas and Europe are 
by far the WHO regions with the most introductions, 85% and 77% of 
their countries having already introduced, respectively. The annual rate 
of new introductions peaked in 2019 with 16 countries, compared with 
previous years when the average was relatively steady at approximately 
7–8 introductions per yar (Fig. 2). It took less than a decade for 80% of 
HICs to introduce the HPV vaccine. LMICs not only started introducing 
later, they introduce at lower pace, and they are also more than twice as 
many LMICs than HICs, so they still lag far behind with only 41% of 
LMICs have introduced by the end of 2019 (Fig. 2). Importantly, the 
trend has shifted, and of the new introductions in 2019, 87% were in 
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LMICs: 6 in sub-Saharan Africa (The Gambia, Liberia, Côte d’Ivoire, 
Kenya, Malawi and Zambia), 5 in Latin America and the Caribbean 
(Costa Rica, Dominica, Grenada, Saint Kitts and Nevis, and Saint Lucia) 
and 3 in Asia and the Pacific (Uzbekistan, Maldives, and Solomon 
Islands). To date 19 LMICs received Gavi support, that represents 35% of 
LMICs. 
By 2019, almost one third of the programs (33 out of 107) were 
“gender neutral” (GN) in the sense that both girls and boys receive the 
vaccine. In 2019, four programs started as GN (Dominica, Niue, Saint 
Kitts and Nevis, and Saint Lucia) and 10 more expanded vaccination to 
males (Belgium, Belize, Chile, Denmark, Germany, Guyana, Ireland, 
Luxembourg, United Kingdom, and Uruguay). GN programs are from 
HICs (79%) or upper-middle-income countries (21%) (Figs. 2 and 3). 
Most programs (47%) included age 12 years as the main age target, 
single or in combination with other ages. Usually, LMICs targeted 
younger girls (9–10 years) than HICs (11–13 years). As it is shown in 
Supplementary Fig. 6, at least 35 million girls aged 9–14 were targeted 
in 2019 either under a single or a multiple cohort strategy, comprising 
10 million from HICs and 25 million from LMICs. 59% of programs 
delivered HPV vaccines through schools, either as the main strategy or 
in combination with facility-based delivery. While in HICs programs 
were similarly distributed between school-based and facility-based 
(39% and 48% respectively), in lower-middle- and low-income coun-
tries almost all programs were school-based or mixed (90%). Most 
countries used a two-dose HPV vaccination schedule with a 6-month 
interval, although a growing number of countries (seven) already 
report using a 12-month interval between the first and second dose 
(Chile, The Gambia, Indonesia, Malawi, Solomon Islands, Zambia and 
Zimbabwe). Only three countries (Bahamas, Japan and Singapore) still 
recommend the three-dose schedule for ages below 15 years. In 2019, 
76% of programs used a single cohort approach (either age-based or 
school-grade based, 60% and 40% respectively). Fig. 3 presents an 
overview of single vs. multiple cohort changes over time. At least 18 
programs have changed from a multiple-cohort strategy to a single- 
cohort one, while nine have done the other way around. Most coun-
tries (87%) have changed the eligibility criteria at least once (between 
single and multi-cohort or between age and school grade approach), 
61% of them during the first two years of the Program. 
Globally, we estimated that in 2019 about 15% of girls and 4% of 
boys were vaccinated with the full course of vaccine and 20% and 5% 
received at least one dose respectively. Looking at SDG regions, 
Australia and New Zealand, and Latin America achieved the highest 
HPVc coverages (77% and 61% respectively), followed by Europe and 
North America (35%). In contrast, as shown in Table 1, Northern Africa, 
Oceania (excluding Australia and New Zealand), and Asia all had very 
low coverage rates. Despite that only a third of Sub-Saharan African 
countries have included HPV vaccination in the national schedule, this 
region already achieved nearly 20% coverage due to overall good pro-
gram performance (Table 1). Although more than half of countries 
(55%) globally have introduced the HPV vaccine, due to different pop-
ulation sizes, 70% of girls globally still live in countries that have not yet 
introduced. This is explained by the fact that 7 of the 10 top most 
populous countries have not yet introduced - or only at sub-national 
level, including China, India, Nigeria, Pakistan, Indonesia, Bangladesh, 
and Russia. This dramatically affects global coverage estimates which 
reached only 15% in 2019 (Fig. 4 and Table 1). It is important to bear in 
mind that of the 30% of the world’s population of girls aged 9 to 15 
years, the ones who live in countries with a HPV vaccine program, just 
over half (53% average performance coverage) received the final dose of 
HPV. Fig. 4 shows a gradual upward trend of global coverages based on 
both coverage indicators, but this increase is linked more to the growing 
number of countries introducing the vaccine than to improvement in 
program performance. 
Fig. 5 presents country-specific HPV vaccination program coverage 
estimates for 99 countries in 2019 (83 countries both for HPV1 and 
HPVc, 12 for HPV1 only and 4 for HPVc only, 8 countries did not report 
data and estimates could not be produced). HPV vaccine program per-
formance coverage averaged 67% for the first dose and 53% for the final 
dose. LMICs performed better than HICs with a higher median coverage 
for HPV1 coverage (80% versus 72%, respectively), but the mean 
dropout rates in LMICs were higher (18% vs 11%). School-based de-
livery strategies and single-cohort approaches on average performed 
better (HPVc Program coverage 56% and 58% respectively) than 
facility-based programs (38%). Most of countries with only an HPV1 
estimate were countries that introduced in the second semester of 2019 
and HPVc was not yet administered. Out of the 87 countries with an 
available HPVc estimate, only five (6%) countries achieved coverage 
with the final dose over 90%, which is the target coverage by 2030 for 
the global cervical cancer elimination strategy. Only 22 countries (21%) 
achieved coverage over 75% while 35 (40%) had a HPVc coverage of 
Fig. 1. WHO member states with HPV vaccination in their national immunization program, as of June 2020. 
It does not include territories, state of free-association, or semi-autonomous regions. The boundaries and names shown and the designations used on this map do not 
imply the expression of any opinion whatsoever concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation 
of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 
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50% or less, and 14 (16%) even below 20% coverage. As comparison, 
only 3% of countries globally report with the third dose of Diphtheria, 
Tetanus and Pertussis containing vaccine (DTP3) levels below 50%. 
DTP3 coverage among one-year olds is a well-established measure to 
assess the strength of the immunization Program and health systems and 
has been used until recently as eligibility criteria for introducing HPV 
vaccines in Gavi-supported countries (Gavi, the Vaccine Alliance, 2020; 
Kallenberg et al., 2016). Supplementary Fig. 7 shows the complete lack 
of correlation among DTP3 and HPV1 performance estimate. This is a 
rather relevant result and indicates that DTP3 coverage is not a good 
predictor of how well an immunization program will perform to achieve 
HPV vaccine coverage. 
Fig. 2. Cumulative number of countries that have introduced HPV vaccination by sex, year and income level. 
Romania, Lesotho, Kazakhstan stopped their programs in 2011, 2012, and 2015, respectively. In Japan although the vaccine remains in the national immunization 
program and is free for 12–16-year-old girls, all proactive recommendations for it are suspended since 2013. Peru also temporarily stopped the program between 
2012 and 2013. 
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To compare the coverage between boys and girls in GN programs, 
male to female ratios were produced. These M/F ratios were close to or 
below 1 in most of the countries (Fig. 6) indicating good acceptation of 
male vaccination in most of the countries offering gender-neutral 
vaccination. 
Fig. 7 compares, for a selection of 53 countries, the program per-
formance during the first two years of the program with the following 
years using coverage results for the first dose. No significant qualitative 
nor statistical differences were found between the two periods (60% vs 
65% mean coverage of HPV1). Results were similar for different country 
income levels, although HICs bordered on statistical significance (p- 
value=0.053, but only reflects an improvement of 7 percentage points 
from the initial mean) (Fig. 7A). Further stratification by initial coverage 
explained these slight gains. When initial coverages were lower than 
50%, underperforming countries gained on average 15 percentage 
points during the following years, although most remained below 50% 
(Fig. 7B). These findings seem to indicate that, unlike in childhood 
vaccination where the coverage of new vaccines tends to catch up from 
considerably lower levels with the DTP3 coverage reference value after 
some years, the performance during first two years of the HPV vacci-
nation program seems to be a strong predictor of the level of vaccine 
coverage in the subsequent years as experienced so far, showing a rather 
limited improvement. 
4. Discussion 
This work provides the first full overview of the WHO/UNICEF HPV 
vaccine coverage estimates and its methodology, which differs from that 
used for other childhood immunizations as per the WUENIC estimates 
(Burton, 2009). As of June 2020, 107 (55%) of the 194 WHO Member 
States reported introduction of HPV vaccination nationwide or partially 
into their national immunization schedules. The 2019 estimates show 
that program performance was sub-optimal in many countries, including 
high-income countries with the most resources, as is evident from the 
global average with last dose coverage of 53% in countries introduced 
the vaccine. When expressed as coverage of the global population of 
eligible girls (i.e. weighted by population size), global final dose HPV 
coverage is estimated at 15%. This low number is explained by the fact 
that many of the most populous countries have not yet introduced and 
that many of those that have introduced have low performance. 
Regional and income level variations of HPV vaccinate introduction 
confirm and perpetuate known disparities in cervical cancer prevention 
worldwide: the highest burden countries not only have limited second-
ary prevention but are less likely to provide access to vaccination. 
Fortunately, this trend seems to be reversing and 2019 has been an 
especially strong year for HPV vaccination introductions with 14 new 
LMICs now providing the vaccine, catalyzed by three important global 
Fig. 3. Changes over time in national HPV programs (eligibility criteria). 
Catch-up strategies are not included. Single cohort vaccination: only one age or birth cohort is targeted. Multi-age cohort vaccination (MAC): more than one age or 
birth cohort is targeted. 
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policy decisions: 1) a change in the WHO position paper in 2015 
encouraging multi-age cohort vaccination programs in the initial year of 
introduction; 2) the 2015 decision by Gavi to allow countries who pre-
viously graduated from Gavi support prior to 2013 to apply for HPV 
vaccine supply in either 2015 or 2016; and 3) the 2016 decision by Gavi 
to remove the 2-year limited demonstration program requirement prior 
to national introduction. Since 2017, 28 countries have been approved 
by Gavi to introduce HPV vaccine into their national immunization 
programs. Nineteen of these introduced, mostly from Africa. Gavi- 
supported countries outperform higher income countries, even though 
most do not reach the 90% goal. Despite the impressive progress ach-
ieved over the last five years, there is a long way to go to meet the 2030 
elimination targets, both in terms of new introductions and in improving 
coverage of existing programs. 
The 2030 target is considered ambitious, but it is in line with the 
90–95% coverage targets set for childhood vaccines such as DTP and 
measles (World Health Organization, 2020a; World Health Organiza-
tion, 2013). Brisson et al. (Brisson et al., 2020) in their model analysis 
found that HPV vaccination coverage of 90% of girls could lead to the 
elimination of cervical cancer as public health problem in most LMICs 
within a century, but that in high incidence countries (ASR>25 per 
100,000) vaccination alone may not be sufficient to bring the incidence 
below 4 per 100,000 and would require screening of adult women with 
high sensitivity test at least twice lifetime. In a recent series of papers, 
Lehtinen and colleagues (Lehtinen et al., 2019; Vänskä et al., 2020) 
argue that it would be possible to go beyond cervical cancer reduction 
and to even eliminate HPV vaccine types from circulation in a scenario 
of moderately high coverages (over 75%) with gender-neutral vaccina-
tion. For girls only vaccination, they report that much higher coverage, 
above 90% or even 95%, and sustained for a much longer period of time 
will be needed to achieve eradication of the most persistent and carci-
nogenic types such as HPV-16. Yet, in 2019 most countries have HPV 
vaccination coverage of last dose HPV below 75%. 
One of the main challenges ahead is to improve underperforming 
programs. Despite the particularities and differences between countries, 
our results suggest that: 1) coverage reached in the first few years is 
usually the one that is maintained so far; 2) programs performed much 
better in delivering HPV1 than HPVc, with more than half of the 
countries achieving an HPV1 coverage of above 75%; 3) There were no 
significant differences in performance between GN and Girls-only pro-
grams; 4) Catch-up strategies may increase coverage by an average of 
8–10% points, 5) Although managed by the same immunization pro-
gram, HPV vaccination has significant differences compared to the 
childhood vaccines such as the target age group, delivery platforms, 
community outreach communication strategy, that make HPV program 
apart from the rest of childhood vaccines. 
In low-resource settings, adolescents use health services to a much 
lesser extent, and therefore service delivery in schools is more common 
in LMICs (Ladner et al., 2014; Howard et al., 2016). Rwanda is an 
example where high HPV vaccine coverage rates (94% by 2019) have 
been achieved through a school-based strategy with a campaign style 
approach to vaccine delivery (Binagwaho et al., 2012). However, many 
LMICS do not have funded school health programs, making HPV 
vaccination in schools often expensive and hard to sustain. In addition, 
LMICs need to use considerable resources to reach out of school girls. We 
observe that a growing number of LMICs use a combination of several 
vaccine delivery methods including schools, health-centers and the use 
of campaign approaches, in combination with for example child health 
days even though schools may continue to be the place where most doses 
are provided (Wigle et al., 2016). Analysis of the 2019 data show that 
LMICs have been outperforming HICs with first-dose coverage. How-
ever, this should be interpreted with caution by the fact that most of the 
LMICs are recent introductions and that many of them have used 
campaign style delivery. It remains a question whether this approach is 
Table 1 
Global and regional female HPV vaccine coverage estimates in 2019, based on program performance coverage indicator.  
First dose (HPV1) Final dose (HPVc)  
N countries with data 
Coverage (weighted by population size) 
N countries with data 
Coverage (weighted by population size)  
% (95% CI) % (95% CI) 
Global 
Females 95 20% (10–36%) 87 15% (7–26%) 
Males* 22 5%* (0.8–13%) 16 4%* (0.4–9%)  
Income level 
High income 43 50% (35–63%) 44 40% (28–53%) 
Low and middle income 52 16% (8–31%) 43 12% (5–24%) 
Upper middle income 32 27% (9–63%) 30 23% (7–54%) 
Lower middle income 13 4% (1–14%) 9 1% (0.2–4%) 
Low income 7 32% (7–56%) 4 23% (2–45%)  
Gavi eligible- countries (2018) 14 12% (4%–32%) 6 7% (1%–21%) 
Non Gavi-eligible countries (2018) 81 28% (14%–50%) 81 23% (11%–41%)  
SDG regions 
Sub-Saharan Africa 16 31% (12–54%) 10 20% (5–39%) 
Northern Africa and Western Asia 5 1% (0.2–5%) 5 1% (0.1–4%) 
Central and southern Asia 5 3% (0.1–23%) 3 1% (0–10%) 
Eastern and south-eastern Asia 8 6% (0.8–28%) 8 4% (0.2–23%) 
Latin America and the Caribbean 28 73% (50–83%) 25 61% (35–75%) 
Oceania (excl. AUS/NZL) 6 11% (0.8–74%) 5 4% (0.2–39%) 
Australia and New Zealand 2 86% (71–89%) 2 77% (67–79%) 
Europe and northern America 25 46% (25–59%) 29 35% (21–49%)  
WHO region 
AFRO 16 31% (12–53%) 10 19% (5–38%) 
PAHO 30 70% (55–81%) 27 55% (38–72%) 
EMRO 1 0.2% (0–0.7%) 1 0.2% (0–0.7%) 
EURO 29 33% (17–52%) 32 24% (12–41%) 
SEARO 5 3% (0.1–26%) 4 2% (0.1–23%) 
WPRO 14 6% (1–39%) 13 4% (0–34%) 
Country-specific HPV vaccination program coverage estimates were available for 99 countries in 2019 (83 countries both for HPV1 and HPVc, 12 for HPV1 only and 4 
for HPVc only). *Global male vaccination coverage included as a comparison. Due to limited data, all other estimates are for females only 
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sustainable and whether adaptations of the strategy will affect future 
results. Striking differences between programs, as observed in Fig. 5, 
indicate the need for further studies on determinants of performance. 
According to available data from a variety of sources up to 40 
additional countries have plans or are projected to introduce HPV vac-
cine in the national schedule by end of 2023. These plans are being 
affected by the recent, worldwide shortage of HPV vaccine, which is 
predicted to last until 2023, at the earliest until the current vaccine 
manufacturers ramp up their production and additional manufacturers 
enter the market (World Health Organization, 2019d). These shortages 
led WHO’s Strategic Advisory Group of Experts (SAGE) to adapt its 
recommendations towards postponing multi age cohort at introduction 
and male vaccination programs as well as to extend the dosage intervals 
in case of need (World Health Organization, 2019c). It is unfortunate to 
observe that multi age catch up and introductions in LMICs have and 
will likely continue to be affected of the next years by the global vaccine 
shortage, while a record number of upper-middle and high-income 
countries have added male vaccination to their program in the last 
2–3 years. In those countries that offer HPV vaccination to males, it is 
overall well accepted and the analysis of the uptake of HPV by males 
compared to females (Fig. 6) shows male HPV coverage often rapidly 
converges with coverage among females. However, it is important to 
note that trends in coverage do not seem to show that including boys 
improves coverage for girls. 
The 2020 COVID-19 pandemic is affecting HPV programs in a variety 
of ways. School closures and interruption of routine vaccination pro-
grams have halted HPV delivery in the majority of countries and are 
having an impact on other antigen coverages, as well (World Health 
Organization, 2020e). In August 2020, around 70 countries had 
reportedly interrupted their immunization programs due to the global 
pandemic (World Health Organization, 2020e; Organización Panamer-
icana de la Salud, 2020) . Several of the planned HPV introductions in 
2020 are expected to be delayed. While the flexibility of the HPV vaccine 
schedule (age and interval) may help to mitigate the negative impact of 
these interruptions in the short term due to the possibility to catch up 
any missed cohorts and doses later in 2020 or in 2021, the longer term 
effects of the predicted economic downturn on the plans to introduce in 
the nearly 70% of global cohort of girls could be far reaching. 
Defining meaningful and comparable coverage indicators for HPV 
vaccination is complex due to the wide age range targeted (adolescent 
girls) and the heterogeneity both inter- and intra-countries. The WHO/ 
UNICEF HPV coverage estimate methodology (see Supplementary ma-
terial - section 1) uses two complementary indicators: program perfor-
mance and coverage by age 15. The first indicator is more informative 
for HPV programs because it monitors the yearly performance of the 
program reaching the population defined as eligible for vaccine (by age 
or grade) that year and can signal vaccination challenges and progress in 
a timely manner. It is also a country-specific indicator (specific target), 
which makes the comparison with other countries difficult as the defi-
nition of the numerators and denominators differ. By contrast, the in-
dicator of coverage by age 15 assesses the population protection level at 
15 years of age regardless of the target age and year of vaccination. It 
therefore allows for better comparison of vaccine coverage trends over 
time, can point to missed cohorts due to changes in recommended age or 
program disturbance and facilitate comparisons across countries. The 
main disadvantage is the time lag. This indicator also presents certain 
calculation challenges because a cohort methodology is required to 
transform reported numerators into birth-cohort coverages using the 
population age and the calendar year of the estimation. It is thereby 
highly dependent on the consistency and quality of reporting from the 
Fig. 4. Global estimates of HPV vaccination coverage by age 15 years over time 2010–2019.  
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previous 5 years. To overcome some of these limitations and improve 
accuracy in coverage estimation for HPV vaccination, increase use of 
birth cohort approach for registration and reporting of HPV vaccination 
data is highly recommended (Sayinzoga et al., 2020). 
The quality of denominator data for HPV vaccination target ages 
presents a specific problem. Whereas programs with the help of national 
statics bureaus have decades of experience establishing the birth cohort 
that serves as denominator for childhood vaccines, much less attention 
has gone into the precision of identifying the size of 9 or 12-year-old 
cohorts. Census data in many countries are outdated and projection 
quality and factors like internal migration (often to attend school), 
conflict, as well as emigration may affect the quality. Additionally, 
countries using school grades as eligibility criteria often use data from 
other sources such as the ministry of education which may have its own 
challenges. Partly to overcome these country level challenges and to 
establish a comparable historical coverage series, the WHO/UNICEF 
methodology has opted to use the UN Population Division population 
estimates for denominators for each country. In future, for countries 
with recent census and good age specific population, country de-
nominators reported through the JRF may be used instead where 
possible. 
While expensive to implement, periodic high quality population- 
based EPI vaccination coverage surveys using the revised WHO meth-
odology for immunization surveys (World Health Organization, 2018d) 
could provide estimates of HPV national coverage which could then be 
compared with estimates from either country administration data and 
Fig. 5. Country-specific HPV vaccination program coverages estimates for girls by income level in 2019. 
*Coverage over 100%. Truncated to 99%. May indicate problems with the accuracy of data. 
Coverages reflect different ages at vaccination within the 9–14 year of age range recommended by WHO depending on the target population of each program. 
Countries are named using their iso3 coding https://unstats.un.org/unsd/tradekb/knowledgebase/country-code;https://www.iso.org/iso-3166-country-codes.html 
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inform WHO UNICEF HPV estimates. There are already plans to include 
a module for HPV coverage in existing multi indicator household sur-
veys. Additionally, a few countries have embarked on conduct of a 
multi-district HPV vaccination coverage survey, with criteria-based se-
lection of districts that broadly represent the programmatic and popu-
lation characteristics of the country’s HPV vaccination program. This 
approach was recently used in Zimbabwe to validate national estimates 
of HPV vaccination among the multi-age cohort of 10 to 14 year old girls 
(LaMontagne et al., 2020). Electronic immunization registries may 
improve data quality and be able to reduce the implementation cost of 
such a national survey by providing an easier to access sampling frame 
from which to make the estimate (Pan American Health Organization, 
2017). Further linking with electronic medical records may facilitate the 
assessment of the impact of vaccination and the linkage with cervical 
cancer screening practices. 
Collecting and reporting the data on HPV vaccination by age, dose 
and -in some cases - sex has proven quite challenging particularly in the 
early years of the program. In the absence of international guidance on 
HPV reporting, various practices existed that led difficulties to system-
atize the WHO/UNICEF historical data sets. It is crucial to build and 
strengthen capacity at the local level on the value and the importance of 
data utilization and continuously motivate to improve the quality of 
data (Pan American Health Organization, 2019). The last two years 
improving the quality of data in collaboration with the country pro-
grams has been a priority, including the recovery of unreported data 
from previous years. While the annual update of vaccine coverage will 
always include review of the historical dataset – for example by applying 
the new 2019 UN population data for denominator calculation as was 
done for the 2019 update - HPV vaccine coverage estimates have also 
been updated based on revision and further completion of historical data 
by the national programs. In the 2019 update, considerably less missing 
data points remained in the WHO/UNICEF historical data set than in 
2018. Even so, data quality issues or missing data prevented the calcu-
lation of performance indicator in nearly one third of estimates in 2010, 
whereas by 2019 this percentage has been reduced to 11%. In addition, 
interpolation and extrapolation techniques were used to compute a 
further 7% of the estimates. While initially 2019 reporting was more 
incomplete due to COVID-19 interruptions, the final quality of the data 
reporting on HPV improved in 2019 compared to earlier years. The 
convergence found in the sensitivity analysis on the historical dataset 
indicates that the way missing data were treated was acceptable, espe-
cially for the performance indicator. However, to further increase 
Fig. 6. Intra-country ratio of male to female (M:F) HPV vaccine program coverage.  
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completeness and quality of reporting and the use of well-functioning 
vaccination registries will be necessary. 
Another limitation is the lack of uncertainty estimates associated 
with the country-specific estimates. As the estimates are not based on a 
probability sample, no measurement error is computed, and it is not 
possible to calculate a confidence interval or other ways to assess the 
quality of the estimate. Several projects are underway to approximate 
either confidence intervals or a reliability index. 
4.1. Conclusion 
In conclusion, the pace of HPV introductions has not diminished in 
spite of growing supply constraints in over the last few years. A record 
number of introductions was observed in 2019 most of which in LMICs 
where access has been limited. The average performance of HPV pro-
grams is far below the performance the same countries reach with their 
childhood vaccines. Still there is a long way to go to meet the 2030 
Fig. 7. Box plots and comparison of means for HPV1 coverage program performance between the first two years of implementation and the following years. 
The box plots show the minimum value, the first quartile, the median, the third quartile and the maximum value. The first quartile marks one end of the box and the 
third quartile marks the other end of the box, with the median as a horizontal line in between. The middle 50% of the coverages fall inside the box. The median may 
differ from the mean shown below the x-axis labels. 
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elimination targets, both in terms of new introductions and in improving 
coverage of existing programs, but in every geography we have exam-
ples of programs that met the 90% target. The use of electronic immu-
nization registries, surveys and overall data quality improvement 
measures will further increase the accuracy of HPV vaccination coverage 
estimates. 
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